Product Hopping May Violate Antitrust Laws, FTC Says
The Federal Trade Commission is taking drugmakers to task for tweaking products to maintain exclusivity and block generic competition, warning the practice — known as product hopping — may violate antitrust laws.
In an amicus brief, filed Sept. 30 in the Third Circuit appeals court, the FTC says drugmakers can stifle competition by tweaking products and then discouraging use of the older version through tactics such as restricted supply, price increases and flooding doctors with samples of newer versions.
“That shift in prescriptions is generally a one-way street: once doctors prescribe a medicine and find that it works, they are generally reluctant to switch users back to the original formulation even if a cheaper generic version of it later becomes available,” the commission says.
The brief was filed in an appeal of Mylan’s lawsuit accusing Warner Chilcott and Mayne Pharmaceuticals of using the technique to prevent generic competition of their acne medication Doryx. The FTC takes no position on whether Mylan should prevail, but says the lower court failed to understand that generics are unique sources of competition for brandname prescription drugs.
In its lawsuit, Mylan claimed that the brandmakers maintained a monopoly for Doryx (doxycycline) by suppressing generic competition through three insignificant reformulations involving dosage level or distribution type — capsule or tablet — of the drugs, coupled with efforts to drop the original formulation.
In April, the U.S. District Court for the Eastern District of Pennsylvania ruled that a brandmaker may thwart automatic substitution so long as generics makers remain hypothetically free to pursue new distribution alternatives.
The decision in Mylan Pharmaceuticals v. Warner Chilcott Public Ltd. et al. granted defendants’ motion for summary judgment (Generic Line, April 29). — Jonathon Shacat
Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar, Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process — a $287 Value!
LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.
FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing